<DOC>
	<DOCNO>NCT00171834</DOCNO>
	<brief_summary>The study objective evaluate maximum tolerate dose , safety efficacy patupilone patient NSCLC progress prior chemotherapy .</brief_summary>
	<brief_title>Dose Escalating Study Safety Efficacy Patupilone , q3w , Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Patients histologic cytologic confirmation unresectable locally advanced metastatic NSCLC ( stage IIIB pleural effusion / stage IV ) document first line therapy . Prior treatment platinumcontaining regimen Age ≥18 year . Performance status 01 WHO scale . Life expectancy ≥3 month . NSCLC patient least one measurable lesion define modified RECIST criterion . If patient previous radiation marker lesion ( ) , lesion must demonstrate progression since radiation . NSCLC patient control brain metastasis eligible enrol brain metastasis cohort MTD . `` Controlled brain metastasis '' patient define patient neurologically stable , i.e . experienced increase dose steroidal anticonvulsive therapy least 14 day prior study entry . Patients brain metastasis must verify metastasis secondary NSCLC base histology primary temporal sequence event ( note : patient eligible even lung disease quiescent ) . Patients brain metastasis must show evidence residual disease progression disease since prior radiological surgical therapy . Patients brain metastasis least one bidimensionally measurable intracranial lesion minimum diameter 2 cm . Multifocal disease permit , eligibility BM patient present 6 intracranial lesion discuss Novartis prior enrol patient . Patients adequate hematologic parameter : ANC ≥1.5 x 10^9/L ; Hb ≥9.0 g/dL , Platelet count ≥100 x 10^9/L ( untransfused ) . Demonstrate follow blood chemistry laboratory value : total bilirubin ≤ 1.5 x ULN ; AST/ALT ≤ 2.5 X ULN ; ( ≤ 5 x ULN hepatic metastasis present ) alkaline phosphatase ≤ 2.5 x ULN ; ( ≤ 5 x ULN hepatic and/or bone metastasis present ) serum creatinine &lt; 2 x ULN . Female patient must negative serum pregnancy test screening . ( Not applicable patient bilateral oophorectomy and/or hysterectomy patient postmenopausal ) . All patient reproductive potential must agree use effective method contraception study three month follow termination treatment . All patient must use barrier method contraception sexual intercourse avoid first 5 day patupilone infusion . Written informed consent must obtain . Patients receive one prior chemotherapy regimen systemic antineoplastic treatment include immunotherapy . Patients receive investigational compound within past 28 day plan receive investigational drug participate study . Patients brain metastasis receive prior chemotherapy regimen systemic antineoplastic treatment brain metastasis . Patients brain metastasis experience dose increase 25 % previous dose , concomitant steroidal anticonvulsive therapy within 14 day prior study entry . Patients brain metastasis receive steroidal anticonvulsive therapy dose increase require within 14 day prior start study drug . Patients brain metastasis leptomeningeal disease . Patients brain metastases extracranial metastasis two organ . Patients peripheral polyneuropathy &gt; Grade 1 . Patients unresolved diarrhea &gt; Grade 1 . Patients receive hematopoietic growth factor except erythropoietin ( refer Section 3.4.4 ) . Severe cardiac insufficiency ( NYHA III IV ) , uncontrolled and/or unstable cardiac coronary artery disease . Patients take warfarin agent contain warfarin , exception low dose warfarin ( 1 mg less daily ) administer prophylactically maintenance indwell line port . Patients recover fully surgery cause , include brain metastasis patient biopsy surgical resection brain tumor within 2 week prior start study drug fully recover prior biopsy surgical resection . Patients receive radiation therapy chemotherapy within last four week . Palliative radiotherapy metastasis extremity allow lesion use tumor marker . Patients presence active suspect acute chronic uncontrolled infection , include abscess fistula . Patients know HIV positive . History another malignancy within 3 year prior study entry , except curatively treat nonmelanotic skin cancer cervical cancer situ . For patient enrol brain metastasis cohort , follow exclusion MRI imaging : Cardiac pacemaker Ferromagnetic metal implant approve safe use MRI scanner Claustrophobia Obesity ( exceed limit scan equipment ) Pregnant lactate female . A history noncompliance medical regimen inability unwillingness return schedule visit . Other protocoldependent inclusion / exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>EPO</keyword>
	<keyword>EPO906</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Lung metastasis</keyword>
	<keyword>NSCLC</keyword>
</DOC>